Clinical Trials Logo

Acquired Aplastic Anemia clinical trials

View clinical trials related to Acquired Aplastic Anemia.

Filter by:
  • None
  • Page 1

NCT ID: NCT03904134 Recruiting - Clinical trials for Acute Myeloid Leukemia

Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation

BMT CTN 1702
Start date: June 14, 2019
Phase: N/A
Study type: Interventional

The purpose of this study is to determine if a search strategy of searching for an HLA-matched unrelated donor for allogeneic transplantation if possible then an alternative donor if an HLA-matched unrelated donor is not available versus proceeding directly to an alternative donor transplant will result in better survival for allogeneic transplant recipients within 2 years after study enrollment.

NCT ID: NCT03413306 Recruiting - Clinical trials for Acquired Aplastic Anemia

Eltrombopag+hATG+CsA vs. hATG+CsA in Children With Severe AA

Start date: December 10, 2016
Phase: Phase 3
Study type: Interventional

The analysis of our own clinical data suggests that majority of the hematologic responses observed after the course of h-ATG/CsA is partial, and about 10% tend to have cyclosporine dependence. The aim of the current study is to improve the rate and the quality of hematologic response as well as to prevent delayed complications such as relapse and clonal progression by means of adding eltrombopag to standard immunosuppressive therapy

NCT ID: NCT03047746 Recruiting - Clinical trials for Paroxysmal Nocturnal Hemoglobinuria

Unrelated And Partially Matched Related Donor PSCT w/ TCR αβ Depletion for Patients With BMF

Start date: February 1, 2017
Phase: N/A
Study type: Interventional

This is a single arm pilot study using TCR alpha/beta+ T cell-depleted peripheral blood stem cells (PBSC) from closely matched unrelated donors or partially matched/haploidentical related donors for hematopoietic stem cell transplant (HSCT) in patients with acquired and inherited bone marrow failure (BMF) syndromes.

NCT ID: NCT01844635 Recruiting - Clinical trials for Acquired Aplastic Anemia.

Randomised Study Comparing Different Dosages of Rabbit ATG in Patients With SAA

Start date: May 2012
Phase: Phase 3
Study type: Interventional

The objective of this study is to evaluate the feasibility and effectiveness of immunosuppressive therapy (IST) using rabbit anti-thymocyte globulin (ATG) (Thymoglobuline, Genzyme) for patients with very severe aplastic anemia (VSAA) and severe aplastic anemia (SAA) as a primary therapy. The primary endpoint is the response rate (complete response (CR) + partial response (PR)) at day 180 after the start of IST. Secondary endpoints include evaluation of the presence and frequency of Epstein-Barr virus (EBV)-reactivation and EBV-associated lymphoproliferative disorder (EBV-LPD), Cytomegalovirus(CMV)-reactivation and CMV associated diseases, the response rate (CR+PR) on Day 360 after the start of IST, relapse rate and overall survival.

NCT ID: NCT01759732 Recruiting - Clinical trials for Acquired Aplastic Anemia

Haploidentical Stem Cell Transplantation for Children With Acquired Severe Aplastic Anemia

Start date: September 2012
Phase: Phase 2
Study type: Interventional

Rationale: Fludarabine, cyclophosphamide, anti-thymocyte globulin and low-dose total body irradiation (LD-TBI) may induce the engraftment cross the immunologic barrier in the setting of HLA-haploidentical allogeneic hematopoietic cell transplantation. In addition, depletion of CD3 cells may contribute to prevent developing severe acute graft versus host disease (GVHD) in haploidentical transplantation. Purpose: Phase II trials to evaluate the efficacy of haploidentical stem cell transplantation with fixed dose of T cells after in vitro T cell depletion using CD3 monoclonal antibody for children with acquired severe aplastic anemia

NCT ID: NCT01343953 Completed - Relapse Clinical Trials

Cord Blood Transplantation in Severe Aplastic Anemia

APCORD
Start date: May 2011
Phase: Phase 2
Study type: Interventional

This is a Prospective Phase II Study to evaluate Cord Blood Transplantation in Inherited or Acquired Severe Aplastic Anemia Refractory or in Relapse after Immunosuppressive Therapy in the absence of an HLA identical donor;